Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Ser4.5
L-Serine – Forschung
Hilft wahrscheinlich
26 begutachtete Studien
Was die Evidenz sagt
Hilft wahrscheinlich
L-Serine scheint in 6 von 6 Studien mit messbaren Effekten zu helfen — die Evidenz tendiert klar ins Positive.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 2011–2026 mit einer typischen Studiengröße von 46 Teilnehmenden.
Basierend auf 26 Studien · 1 Meta-Analyse · 11 RCTs · 2,625 Teilnehmende insgesamt
Konfidenz
Hohe Konfidenz
Was die Studien gefunden haben
6geholfen· 20 weitere ohne bewertete Effektdaten
Nach Outcome
Therapeutic & clinical
Hilft wahrscheinlich13 Studien
Cognitive function
Hilft wahrscheinlich5 Studien
Depression & mood
Überwiegend Mechanismus / Beobachtung4 Studien
ALS & motor-neuron disease
Zu wenige bewertete Studien2 Studien
Glucose & metabolic
Zu wenige bewertete Studien2 Studien
Safety profile
Zu wenige bewertete Studien2 Studien
Neuroprotection & brain agingUnterstützt die Phospholipid-Synthese und die Integrität neuronaler Membranen · 8-12 Wochen
Zu wenige bewertete Studien1 Studie
Heart & blood pressure
Zu wenige bewertete Studien1 Studie
Joint pain & arthritis
Zu wenige bewertete Studien1 Studie
In Zahlen
Aus 17 Studien mit messbaren Effekten gezogen
Wahrscheinlich echte Effekte
100%
über Studien hinweg
Untersuchte Personen
2,625
typische Studie: 46 Personen
Stärkste Designs
12
1 gepoolt, 11 randomisiert
Zeigte Nutzen
100%
6/6 Studien
Wie lange Studien liefen
1–3 Monate
1
3+ Monate
1
Untersuchte Populationen
Patients with hereditary peripheral neuropathies1
Patients with developmental and epileptic encephalopathies1
Major depressive disorder patients1
Patients with serine metabolism disorders1
Aktives Forschungsgebiet
20 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2021
201120182026
1Treatable variants in hereditary peripheral neuropathiesSystematische ÜbersichtCited 16×n=2,046 · very large study2021
The 'treatable' variants highlighted in this project will be flagged in the treatabolome database to alert clinicians at the time of the diagnosis and enable timely treatment of patients with hereditary peripheral neuropathies.
Jennings MJ et al. · Journal of neuromuscular diseases (2021)
The 'treatable' variants highlighted in this project will be flagged in the treatabolome database to alert clinicians at the time of the diagnosis and enable timely treatment of patients with hereditary peripheral neuropathies.
2Precision therapies for developmental and epileptic encephalopathiesSystematische ÜbersichtCited 15×2025
Additionally, the importance of enhancing access to genetic testing, conducting robust natural history studies, and employing innovative clinical trial designs is emphasized.
Samanta D et al. · Pediatric neurology (2025)
Additionally, the importance of enhancing access to genetic testing, conducting robust natural history studies, and employing innovative clinical trial designs is emphasized.
Future directions focus on addressing the challenges in developing and implementing gene-based therapies, integrating systems biology, leveraging artificial intelligence for data analysis, and fostering collaboration among stakeholders.
The rapidly advancing field of precision therapeutics for DEEs holds promise to improve outcomes through tailored, equitable, and patient-centered care.
3Peripheral blood metabolites in major depressive disorderMeta-AnalyseCited 171×n=46 · small study2021
MDD patients were characterized by higher levels of asymmetric dimethylarginine, tyramine, 2-hydroxybutyric acid, phosphatidylcholine (32:1), and taurochenodesoxycholic acid and lower levels of L-acetylcarnitine, creatinine, L-asparagine, L-glutamine, linoleic acid... compared with controls.
Pu J et al. · Molecular psychiatry (2021)
Pathway and network analyses revealed altered amino acid metabolism and lipid metabolism, especially for the tryptophan-kynurenine pathway and fatty acid metabolism, in the peripheral system of MDD patients.
Our findings may facilitate biomarker development and the elucidation of the molecular mechanisms that underly MDD.
4L-serine homeostasis in health and diseaseSystematische ÜbersichtCited 42×2023
A serine tolerance test may provide a quantitative readout of l-serine homeostasis that identifies patients who may be susceptible to neuropathy or responsive to therapy.
Handzlik MK et al. · Annual review of nutrition (2023)
Compromised regulation or activity of l-serine synthesis and disposal occurs in the context of genetic diseases as well as chronic disease states, leading to low circulating l-serine levels and pathogenesis in the nervous system, retina, heart, and aging muscle.
Dietary interventions in preclinical models modulate sensory neuropathy, retinopathy, tumor growth, and muscle regeneration.
A serine tolerance test may provide a quantitative readout of l-serine homeostasis that identifies patients who may be susceptible to neuropathy or responsive to therapy.
This review aims to summarize the research progress of serine in diseases, propose the problems that need to be solved in the future, and provide guidance for subsequent research and development.
Li P, Wu X, Huang Y, Qin R, Xiong P, Qiu Y. · Frontiers in cellular and infection microbiology (2025)
An increasing number of studies have demonstrated that L-serine is widely used in the adjuvant therapy of many diseases (e.g., inflammation, infections, fibrosis, and tumors).
Here, we summarize the synthesis and metabolism of serine followed by its functions in health and disease.
Moreover, we delineate the potential mechanisms whereby L-serine is involved in the occurrence and progression of respiratory diseases.
6SLC1A4 role in neurodevelopment and neurodegenerationÜbersicht2025
This review examines the role of SLC1A4 in neurodevelopment and neurodegeneration and assesses the therapeutic potential of serine supplementation to treat neurodevelopmental symptoms associated with mutations in SLC1A4 , as well as schizophrenia, depression, traumatic brain injury, and Alzheimer's and Parkinson's diseases.
Elazar D, Alvarez N, Drobeck S, Gunn TM. · International journal of molecular sciences (2025)
In the brain, SLC1A4 plays an important role in transporting levo (L) and dopa (D) isomers of serine.
L-serine is required for many cellular processes, including protein and sphingolipid synthesis, while D-serine is a co-agonist required for normal neurotransmission through N -methyl-D-aspartate receptors.
Through its roles transporting L-serine across the blood-brain barrier and regulating synaptic D-serine levels, SLC1A4 helps establish and maintain brain health across the lifespan.
l-Serine and EPA were effective for pain relief in adults with low-back and knee pain after multiplicity adjustment.This trial was registered at the University Hospital Medical Information Network Clinical Trials Registry as UMIN000035056.
Sasahara I et al. · The Journal of nutrition (2020)
l-Serine and EPA were effective for pain relief in adults with low-back and knee pain after multiplicity adjustment.This trial was registered at the University Hospital Medical Information Network Clinical Trials Registry as UMIN000035056.
This study suggests the possibility of personalizing sleep-support supplementation based on personal life habits, sleep conditions, and sleep problems, in addition to the known efficacy of dietary supplements.
Imafuku F et al. · Nutrients (2023)
All the tested supplements were found to ameliorate sleep problems significantly (Analysis 1).
In Analysis 2, the PCs specific to improved subjects were found to differ depending on the dietary supplements and sleep problems.
In addition, subjects who consumed dairy products often showed improvement in their sleep problems with all the tested supplements.
9Clinical improvement in GRIN2B-NDD patientsRCT2025
These pioneering n-of-1 trials provide insights into l-serine's potential for GRIN2B-NDD, with improvements in two of four patients, though no clear distinguishing responder-characteristics were identified.
den Hollander B et al. · Molecular genetics and metabolism (2025)
Sehr groß Nutzen
← SchlechterKein EffektBesser →
These pioneering n-of-1 trials provide insights into l-serine's potential for GRIN2B-NDD, with improvements in two of four patients, though no clear distinguishing responder-characteristics were identified.
Future trials should focus on refining patient selection, the use of multiple baseline designs, establishing a core outcome set and pooling treatment data to better understand patient-specific responses.
10ADAS-Cog score improvementRCTCited 65×n=12 · very small study2023
Our results indicate that treatment of AD patients with CMA can lead to enhanced cognitive functions and improved clinical parameters associated with phenomics, metabolomics, proteomics and imaging analysis.
Yulug B et al. · Translational neurodegeneration (2023)
Groß Nutzen
← SchlechterKein EffektBesser →
Likely real
We showed a significant decrease of AD Assessment Scale-cognitive subscale (ADAS-Cog) score on day 84 vs day 0 (P = 0.00001, 29% improvement) in the CMA group.
Moreover, the plasma levels of proteins and metabolites associated with NAD + and glutathione metabolism were significantly improved after CMA treatment.
Our results indicate that treatment of AD patients with CMA can lead to enhanced cognitive functions and improved clinical parameters associated with phenomics, metabolomics, proteomics and imaging analysis.
11Clinical improvement in GRIN-related encephalopathyRCTCited 24×2024
L-serine treatment was associated with significant improvement in the median Gross Motor Function-88 total score (P = 0.002) and the mean Pediatric Quality of Life total score (P = 0.00068), regardless of severity.
Juliá-Palacios N et al. · Brain : a journal of neurology (2024)
Spürbar Nutzen
← SchlechterKein EffektBesser →
Likely real
Their clinical phenotypes showed 91% had intellectual disability (61% severe), 83% had behavioural problems, 78% had movement disorders and 58% had epilepsy.
Expressive (P = 0.005), Personal (P = 0.003), Community (P = 0.009), Interpersonal (P = 0.005) and Fine Motor (P = 0.031) subdomains improved for the whole cohort, although improvement was mostly found in the mild group.
The Growth Scale Values in the Cognitive subdomain of the Bayley-III Scale showed a significant improvement in the severe group (P = 0.016), with a mean increase of 21.6 points.
In terms of intestinal metabolites, the levels of acylcarnitine18:0 (ACar.18:0), cotinine, N-arachidonoyl-L-serine, phosphatidylcholine ... changed after FMT.
Zhi W et al. · Scientific reports (2024)
Flow cytometry analysis showed the absolute count of plasma B cells decreased in subjects, and this change correlated with alterations in the intestinal microbiota and metabolites.
This study preliminarily evaluates the safety and efficacy of FMT in patients with IgAN.
No significant adverse reactions were observed, and the administration of FMT alongside ACEI/ARB therapy was effective in reducing urinary protein levels in patients with IgAN, a process that may be associated with B-cell immunity.
The protocol called for enrollment of patients with a diagnosis of probable or definite ALS, age 18-85 years, disease duration of less than three years and forced vital capacity (FVC) ≥ 60%.
Of 20 patients enrolled, one withdrew before receiving study drug and two withdrew with gastro-intestinal problems.
15Cognition and mood in older adultsRCTCited 36×n=50 · small study2016
D-serine administration may be a strategy to improve spatial memory, learning and problem solving in healthy older adults.
Avellar M et al. · Oncotarget (2016)
Spürbar Nutzen
← SchlechterKein EffektBesser →
Likely real
D-serine administration improved performance in the Groton Maze learning test of spatial memory and learning and problem solving (F(3, 38)= 4.74, p = 0.03).
Subjects that achieved higher increases in plasma D-serine levels after administration improved more in test performance (r2=-0.19 p = 0.009).
Future studies should evaluate the impact of long-term D-serine administration on cognition in older adults.
The results show that treating patients infected with COVID-19 with CMAs lead to a more rapid symptom-free recovery, suggesting a role for such a therapeutic regime in the treatment of infections leading to respiratory problems.
Altay O et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2021)
Plasma levels of proteins and metabolites associated with inflammation and antioxidant metabolism are significantly improved in patients treated with CMAs as compared to placebo.
A comprehensive analysis of the plasma metabolome and proteome reveals major metabolic changes.
The results show that treating patients infected with COVID-19 with CMAs lead to a more rapid symptom-free recovery, suggesting a role for such a therapeutic regime in the treatment of infections leading to respiratory problems.
17CMTNS improvementRCTCited 96×n=18 · very small study2019
High-dose oral l-serine supplementation appears safe in patients with HSAN1 and is potentially effective at slowing disease progression.
Fridman V et al. · Neurology (2019)
Spürbar Nutzen
← SchlechterKein EffektBesser →
Likely real
After 1 year, the l-serine group experienced improvement in CMTNS relative to the placebo group (-1.5 units, 95% CI -2.8 to -0.1, p = 0.03), with evidence of continued improvement in the second year of treatment (-0.77, 95% CI -1.67 to 0.13, p = 0.09).
Concomitantly, deoxysphinganine levels dropped in l-serine-treated but not placebo-treated participants (59% decrease vs 11% increase; p < 0.001).
High-dose oral l-serine supplementation appears safe in patients with HSAN1 and is potentially effective at slowing disease progression.
18L-serine metabolism in intestinal mucosal homeostasisÜbersicht2026
Finally, we highlight directions for future research to target L-serine as a promising therapy.
Devaux A et al. · Communications biology (2026)
Prokaryotic cells, including Escherichia coli, have developed mechanisms to exploit L-serine to support their growth, virulence, inflammatory and/or carcinogenic properties.
In this review, we summarize current findings on L-serine metabolism in the intestinal mucosal homeostasis, its interactions with microbiota, and its modulation in digestive diseases.
Finally, we highlight directions for future research to target L-serine as a promising therapy.
Understanding these pathways could highlight new therapeutic targets to mitigate brain injury.
Carretero VJ, Álvarez-Merz I, Hernández-Campano J, Kirov SA, Hernández-Guijo JM. · Neural regeneration research (2025)
Blocking N-methyl-D-aspartate receptors prevented neuronal damage in the presence of these amino acids during hypoxia.
Thus, previously unrecognized mechanisms involving non-excitatory amino acids may contribute to the progression and expansion of brain injury in neurological emergencies such as stroke and traumatic brain injury.
Understanding these pathways could highlight new therapeutic targets to mitigate brain injury.
Understanding the role of d-AAs in certain pathological states is helping to identify new therapeutic targets, offering promising opportunities for clinical applications in treating various diseases.
Pollegioni L, Kustrimovic N, Piubelli L, Rosini E, Rabattoni V, Sacchi S. · The FEBS journal (2025)
We have focused on novel findings, based on the latest analytical techniques, that have reshaped our understanding of physiological processes across diverse organisms, from plants to humans.
Beyond neurotransmission, recent studies have highlighted the versatile roles of d-AAs in cancer, inflammation, immune regulation, kidney disease, and diabetes.
Moreover, these studies suggest that the levels of d-AAs in blood and urine could serve as early biomarkers for conditions such as Alzheimer's disease, schizophrenia, and chronic kidney disease.